Article Figures & Data
Figures
- Fig 1.
A, Representative regions of interest shown on a T1WI of the neck acquired 10 minutes after injection of the contrast agent. Regions of interest are drawn on a carotid artery (A) and a metastatic node (N). B, Mean time courses of estimated relaxation rates from the 2 regions of interest in A are plotted against time. Circles and crosses represent actual measurement data points from the selected artery and the node, with the lines connecting the points. Note the region of interest used for the node is only to demonstrate the typical enhancement pattern and temporal resolution of the data. The actual pharmacokinetic analysis was performed for each voxel.
- Fig 2.
Representative parametric maps of a CR patient who showed no viable tumor on pathology from the surgically removed nodes. The arrow on the T2WI image indicates the tumor node studied. The T2W, T1W, and CE images in the top row are windowed to have similar image contrast. The SSM parameter maps are shown by using overlaid color images on an area around the metastatic node indicated by the arrow in the T2WI. The background image of the color maps is a T1W CE image.
- Fig 3.
Scatterplots of volume and pharmacokinetic model parameters of 2 patient groups: CR (n = 24) and PR (n = 9). Individual parameters within each patient group are plotted in their own descending orders.
- Fig 4.
Comparison of patients scanned at 1.5T. There are 17 and 7 patients for the CR and PR groups, respectively. The bars represent the mean values and the error bars represent the standard errors. The asterisk represents a significant (P < .05, 2-tailed t test with unequal variance) difference from the CR mean value.
- Fig 5.
Comparison of pretreatment Ktrans values of the patients who received conventional chemotherapy (n = 17 and 7 for CR and PR, respectively) and those who received immunotherapy with an EGFR-targeting drug, cetuximab (n = 7 and 2 for CR and PR, respectively). The vertical bars represent the mean values, and the error bars represent the SDs.
Tables
No. Sex Age (yr) Primary Tumor Staging Ind. Chemo Conc. Chemo Sg Pa Rs 6MFU 1 M 31 Larynx T4aN2bM0 No CP N CR NED 2 M 72 Unknown TxN2bM0 CM No N CR NED 3 F 68 Tongue T4N2bM0 No CP N CR DM 4 M 68 Tonsil T2N2bM0 No CP N CR NED 5 M 70 Tonsil T4N1aM0 No CP N CR NED 6 M 67 Tongue T4aN2cM0 No CP N CR NED 7 F 79 Unknown T4aN2bM0 CM CM, CP N CR NED 8 M 69 Larynx T3N2cMX CP, DT, 5FU CM N CR NED 9 M 72 Tongue T4N2cM0 CP, DT, 5FU CM N CR NED 10 M 67 Unknown T0N2bM0 CP, DT, 5FU CM N CR NED 11 M 72 Tongue T2N2bM0 No CM N CR NED 12 M 75 Tongue T4N2cM0 TX TX, CP Y N CR NED 13 M 42 Tonsil T2N2bM0 No CP Y N CR NED 14 F 53 Tonsil TxN2bM0 No CP Y N CR NED 15 M 50 Tongue T2N2aM0 CP, DT, 5FU CP Y N CR NED 16 M 59 Tongue T3N2cM0 CP, DT, 5FU CP Y N CR NED 17 M 51 Tongue TxN2bM0 CP, DT, 5FU CP Y N CR DM 18 M 55 Tonsil T3N2bM0 CP, TX CP Y N CR NED 19 F 62 Tonsil T2N2cM0 No CP Y N CR NED 20 M 65 Unknown TxN2bM0 No CP Y N CR NED 21 M 52 Tongue T1N2abM0 CP, DT, 5FU CP Y N CR NED 22 M 59 Tongue T4N2bM0 No CP Y N CR NED 23 M 49 Tonsil T3N2aM0 No CM Y N CR NED 24 M 61 Tongue T3N2aM0 CP CM, CP Y N CR NED 25 M 51 Epiglottis T2N2cM0 TX CP Y P PR DM 26 M 76 Tonsil TxN2bM0 TX CP, TX Y P PR DM 27 M 77 Larynx T2N2bM0 No CP, 5FU Y P PR NED 28 M 56 Larynx T2N3M0 No CP Y P PR DM 29 M 64 Unknown TxN3M0 CP, DT, 5FU CP Y P PR DM 30 M 60 Tonsil T4N1M0 No CP Y P PR NED 31 M 63 Larynx T2N2bM0 CP CP Y P PR DM 32 M 45 Tongue T2N2aM0 No CM, CP Y P PR DM 33 F 48 Tonsil T4bN2bM0 CP, DT, 5FU CM, CP Na PR Relapse a Nodes were not removed because additional therapy was given due to disease progression.
Group No. of Patients Volume (mL) Ktrans (min−1) ve τI (s) CR 24 15.3 ± 3.2 0.64 ± 0.11 0.51 ± 0.04 0.21 ± 0.03 PR 9 27.5 ± 10.1 0.21 ± 0.05 0.48 ± 0.07 0.20 ± 0.04 P valueb .276 .001 .721 .760 a The reported values are mean and standard error.
b The P values were computed using a 2-tailed t test with unequal variance.
In this issue
Jump to section
Related Articles
Cited By...
- Optimal Mass Transport Kinetic Modeling for Head and Neck DCE-MRI: Initial Analysis
- Dynamic Contrast-Enhanced MRI-Derived Intracellular Water Lifetime ({tau}i): A Prognostic Marker for Patients with Head and Neck Squamous Cell Carcinomas
- CT Texture Analysis Potentially Predicts Local Failure in Head and Neck Squamous Cell Carcinoma Treated with Chemoradiotherapy
- Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer: Techniques and Clinical Applications
- Quantitative Diffusion-Weighted MRI Parameters and Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma
- Neuroradiology Back to the Future: Head and Neck Imaging
- Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
- Multiparametric MR Imaging of Sinonasal Diseases: Time-Signal Intensity Curve- and Apparent Diffusion Coefficient-Based Differentiation between Benign and Malignant Lesions
- Prediction of Disease-Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging